A Phase 2 interventional study of aflibercept and High-dose aflibercept in Neovascular (Wet) Age-Related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 46 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 23rd largest by enrollment, is one of 4 that started in 2019, is one of 7 in phase 2, and was the 45th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 4 started in 2019.
This study's enrollment of 106 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
17 studies in Macular Degeneration by Regeneron Pharmaceuticals: 2 open now, 3 under way, 2 of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 17 studies in Macular Degeneration by Regeneron Pharmaceuticals, this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 12th registered.
Regeneron Pharmaceuticals’s Macular Degeneration studies by the year they started, since 2005.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Regeneron Pharmaceuticals’s 17 in Macular Degeneration:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment-naïve patients with neovascular "wet" age-related macular degeneration (nAMD) randomized in a 1:1 ratio
Drug: aflibercept
Treatment-naïve patients with nAMD randomized in a 1:1 ratio
Drug: High-dose aflibercept
Intravitreally (IVT) administered as a liquid formulation in a vial
Also known as: EYLEA®, BAY86-5321
Intravitreally (IVT) administered as a liquid formulation in a vial
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Time frame: Up to Week 44
Number of Participants With at Least One Serious TEAE
Time frame: Up to Week 44
Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye
Center subfield=the circular area in 1 millimeter (mm) diameter centered around the center point of the fovea. Without fluid defined as absence of intraretinal fluid (IRF) and/or subretinal fluid (SRF) in the center subfield. Presence of retinal fluid was assessed by spectral domain optical coherence tomography (SD-OCT)
Time frame: At Week 16
| Milestone | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) |
|---|---|---|
| Started | 53 | 53 |
| Completed | 49 | 51 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Participants | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) |
|---|---|---|
| Participants with at least 1 Ocular TEAE of the Study Eye | 20 | 20 |
| Participants with at least 1 Ocular TEAE of the Fellow Eye | 13 | 13 |
| Participants with at least 1 Non-Ocular TEAE | 24 | 28 |
| Participants | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) |
|---|---|---|
| Participants with at least 1 Ocular Serious TEAE of the Study Eye | 1 | 2 |
| Participants with at least 1 Ocular Serious TEAE of the Fellow Eye | 0 | 0 |
| Participants with at least 1 Non-Ocular Serious TEAE | 4 | 5 |
Center subfield=the circular area in 1 millimeter (mm) diameter centered around the center point of the fovea. Without fluid defined as absence of intraretinal fluid (IRF) and/or subretinal fluid (SRF) in the center subfield. Presence of retinal fluid was assessed by spectral domain optical coherence tomography (SD-OCT)
| Participants | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) |
|---|---|---|
| Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye | 18 | 27 |
Collected over From first dose up to Week 44 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravitreal Aflibercept Injection (IAI) | 0/53 (0%) | 4/53 (7.5%) | 14/53 (26.4%) |
| High-Dose Aflibercept Injection (HD) | 1/53 (1.9%) | 7/53 (13.2%) | 19/53 (35.8%) |
| Event | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) |
|---|---|---|
| Chest painGeneral disorders | 0/53 | 1/53 |
| Non-cardiac chest painGeneral disorders | 0/53 | 1/53 |
| Hepatic encephalopathyNervous system disorders | 0/53 | 1/53 |
| Transient ischaemic attackNervous system disorders | 0/53 | 1/53 |
| Acute left ventricular failureCardiac disorders | 0/53 | 1/53 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/53 | 1/53 |
| GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/53 | 1/53 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/53 | 1/53 |
| ColitisGastrointestinal disorders | 1/53 | 0/53 |
| Small intestinal obstructionGastrointestinal disorders | 1/53 | 0/53 |
| Event | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) |
|---|---|---|
| Neovascular age-related macular degeneration Fellow EyeEye disorders | 3/53 | 4/53 |
| Neovascular age-related macular degeneration Study EyeEye disorders | 4/53 | 2/53 |
| Vitreous detachment Study EyeEye disorders | 3/53 | 4/53 |
| FallInjury, poisoning and procedural complications | 2/53 | 3/53 |
| DizzinessNervous system disorders | 0/53 | 3/53 |
| Conjunctival haemorrhage Fellow EyeEye disorders | 1/53 | 3/53 |
| Vitreous detachment Fellow EyeEye disorders | 3/53 | 1/53 |
| Conjunctival haemorrhage Study EyeEye disorders | 2/53 | 3/53 |
| Age, Continuous(years) | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) | Total |
|---|---|---|---|
| Mean | 77.7 ± 8.27 | 77.0 ± 7.69 | 77.4 ± 7.95 |
| Sex: Female, Male(Participants) | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) | Total |
|---|---|---|---|
| Female | 36 | 30 | 66 |
| Male | 17 | 23 | 40 |
| Race/Ethnicity, Customized(Participants) | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) | Total |
|---|---|---|---|
| Hispanic of Latino | 4 | 2 | 6 |
| Not Hispanic or Latino | 49 | 51 | 100 |
| Race/Ethnicity, Customized(Participants) | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) | Total |
|---|---|---|---|
| White | 51 | 52 | 103 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Other | 1 | 0 | 1 |
| Number of Participants without Retinal Fluid in the Center Subfield of Study Eye(Participants) | Intravitreal Aflibercept Injection (IAI) | High-Dose Aflibercept Injection (HD) | Total |
|---|---|---|---|
| Count of participants | 9 | 10 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Nov 2019 to primary completion in May 2021, 18 months.
Results were first posted in Aug 2023, 2 years 3 months after primary completion. A results delay was requested in May 2022.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 18 months is below that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept